Treat-to-target transformed rheumatoid arthritis management by making remission or low disease activity an explicit therapeutic goal rather than accepting persistent symptoms as inevitable. International recommendations emphasize regular disease-activity assessment, timely adjustment of disease-modifying therapy and escalation when the patient is not reaching target. The approach is supported by randomized and observational evidence showing better functional and structural outcomes when disease activity is controlled early and systematically. For general physicians, the message is particularly relevant because RA is not simply a joint disease: cardiovascular risk, infection risk, osteoporosis, fatigue and extra-articular disease all influence long-term outcomes. Methotrexate remains a cornerstone for many patients, while biologic or targeted synthetic DMARDs are added when response is inadequate. Decisions should consider safety factors, vaccination status and comorbidities. The practical strength of treat-to-target is that it turns follow-up into an active control loop—measure, compare with target, modify treatment and reassess—rather than a series of disconnected visits. This strategy fits the conference's emphasis on practical clinical medicine because it connects evidence with a repeatable workflow that can be implemented outside specialist centers.